CYTK vs. EXAS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CYTK and EXAS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CYTK | EXAS |
|---|---|---|
| Company Name | Cytokinetics, Incorporated | Exact Sciences Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 6.68 billion USD | 10.68 billion USD |
| Exchange | NasdaqGS | NasdaqCM |
| Listing Date | April 30, 2004 | February 1, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CYTK and EXAS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CYTK | EXAS |
|---|---|---|
| 5-Day Price Return | 13.81% | 2.99% |
| 13-Week Price Return | 66.34% | 2.95% |
| 26-Week Price Return | 25.97% | 21.79% |
| 52-Week Price Return | 5.01% | -17.06% |
| Month-to-Date Return | 55.56% | 15.37% |
| Year-to-Date Return | 16.84% | -2.63% |
| 10-Day Avg. Volume | 3.03M | 2.25M |
| 3-Month Avg. Volume | 1.90M | 3.04M |
| 3-Month Volatility | 91.53% | 41.17% |
| Beta | 0.54 | 1.32 |
Profitability
Return on Equity (TTM)
CYTK
-132.03%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
CYTK has a negative Return on Equity of -132.03%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
EXAS
-38.37%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
EXAS has a negative Return on Equity of -38.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
CYTK
-707.17%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
CYTK has a negative Net Profit Margin of -707.17%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
EXAS
-34.19%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
EXAS has a negative Net Profit Margin of -34.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
CYTK
-637.96%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
CYTK has a negative Operating Profit Margin of -637.96%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
EXAS
-34.49%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
EXAS has a negative Operating Profit Margin of -34.49%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | CYTK | EXAS |
|---|---|---|
| Return on Equity (TTM) | -132.03% | -38.37% |
| Return on Assets (TTM) | -45.52% | -16.63% |
| Net Profit Margin (TTM) | -707.17% | -34.19% |
| Operating Profit Margin (TTM) | -637.96% | -34.49% |
| Gross Profit Margin (TTM) | -- | 68.19% |
Financial Strength
Current Ratio (MRQ)
CYTK
6.76
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
CYTK’s Current Ratio of 6.76 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
EXAS
2.89
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
EXAS’s Current Ratio of 2.89 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CYTK
6.03
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.03, CYTK operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
EXAS
0.95
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
CYTK
-16.50
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
CYTK has a negative Interest Coverage Ratio of -16.50. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | CYTK | EXAS |
|---|---|---|
| Current Ratio (MRQ) | 6.76 | 2.89 |
| Quick Ratio (MRQ) | 6.61 | 2.32 |
| Debt-to-Equity Ratio (MRQ) | 6.03 | 0.95 |
| Interest Coverage Ratio (TTM) | -16.50 | -15.18 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CYTK | EXAS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CYTK
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for CYTK is currently unavailable.
EXAS
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for EXAS is currently unavailable.
Price-to-Sales Ratio (TTM)
CYTK
77.04
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
CYTK’s P/S Ratio of 77.04 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
EXAS
3.58
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 3.58 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
CYTK
58.48
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
At 58.48, CYTK’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
EXAS
4.06
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
EXAS’s P/B Ratio of 4.06 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CYTK | EXAS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 77.04 | 3.58 |
| Price-to-Book Ratio (MRQ) | 58.48 | 4.06 |
| Price-to-Free Cash Flow Ratio (TTM) | 115.13 | 84.24 |